Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN).

Autor:	Pla C; Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Tarragona, Spain., Solans M; Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain., Ameijide A; Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Tarragona, Spain., Sanvisens A; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI), Girona, Spain.; Josep Carreras Leukaemia Research Institute, Girona, Spain., Carulla M; Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Tarragona, Spain., Rojas MD; Canary Islands Cancer Registry, Public Health Directorate, Canary Islands Government, Las Palmas, Spain., Alemán MA; Canary Islands Cancer Registry, Public Health Directorate, Canary Islands Government, Las Palmas, Spain., Sáez-Lloret I; Castellón Cancer Registry, Directorate General of Public Health and Addictions, Valencian Government, Castellón, Spain., Díaz-Del-Campo C; Ciudad Real Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain., Marcos-Navarro AI; Cuenca Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain., Sainz-de-Aja L; Basque Country Cancer Registry, Basque Government, Vitoria-Gasteiz, Spain., Aizpurua-Atxega A; Basque Country Cancer Registry, Basque Government, Vitoria-Gasteiz, Spain., Lopez-de-Munain A; Basque Country Cancer Registry, Basque Government, Vitoria-Gasteiz, Spain., Sánchez MJ; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Granada Cancer Registry, Andalusian School of Public Health (EASP), Instituto de Investigación Biosanitaria Ibs.GRANADA, University of Granada, Granada, Spain.; Instituto de Investigación Biosanitaria Ibs.GRANADA, Granada, Spain.; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain., Perucha J; La Rioja Cancer Registry, Epidemiology and Health Prevention Service, Logroño, Spain., Franch P; Mallorca Cancer Registry, Public Health and Participation Department, Palma de Mallorca, Spain.; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain., Chirlaque MD; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Epidemiology, Regional Health Authority, Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia University, Murcia, Spain., Guevara M; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Navarra Cancer Registry, Navarra Public Health Institute, Pamplona, Spain.; Epidemiology and Public Health Area, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Galceran J; Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Tarragona, Spain., Merino S; Department of Health, Asturias Cancer Registry, Public Health Directorate, Asturias, Spain., Marcos-Gragera R; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI), Girona, Spain.; Josep Carreras Leukaemia Research Institute, Girona, Spain.; University of Girona, Girona, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Nov 24; Vol. 12, pp. 1046307. Date of Electronic Publication: 2022 Nov 24 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.1046307
Abstrakt:	Introduction: The aim of this study was to describe incidence, incidence trends and survival patterns of lymphoid neoplasms (LNs) and its subtypes in Spain in the period 2002-2013 using data from the Spanish Network of Cancer Registries (REDECAN). Materials and Methods: Data were extracted from 13 Spanish population-based cancer registries. LNs incident cases were codified using the International Classification of Diseases for Oncology, third edition (ICD-O-3) and grouped according to the WHO 2008 classification. Age-standardized incidence rates to the 2013 European standard population (ASIRe) were obtained. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype. The number of cases in Spain for 2023 was estimated by applying the estimated age-specific rates for the year 2023 to the 2023 Spanish population. Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme method. Sex- and age-specific estimates of 5-year NS were calculated, as well as its changes according to two periods of diagnosis (2002-2007 and 2008-2013). Results: LNs accounted for 69% (n=39,156) of all hematological malignancies (n=56,751) diagnosed during the period of study. Median age at diagnosis was 67 years (interquartile range (IQR) = 52-77). The overall ASIRe was 34.23 (95% confidence interval (CI): 33.89, 34.57) and showed a marked male predominance in almost all subtypes (global sex ratio = 1.45). During the study period, incidence trends of LNs remained stable (APC: 0.3; 95% CI: -0.1, 0.6), nevertheless some subtypes showed statistically significant variations, such as LNs NOS category (APC: -5.6; 95% CI: -6.8, -4.3). Around 17,926 new cases of LNs will be diagnosed in 2023 in Spain. Survival rates differed considerably across age-groups, while they were similar between men and women. Five- year NS was 62.81% (95% CI: 62.1, 63.52) for all LNs, and varied widely across LNs subtypes, ranging from 39.21% to 90.25%. NS for all LNs improved from the first period of diagnosis to the second one, being 61.57% (95% CI: 60.56, 62.61) in 2002-2007 and 64.17% (95% CI: 63.29, 65.07) in 2008-2013. Conclusions: This study presents the first complete and extensive population-based analysis of LNs incidence and survival in Spain. These population-based data provide relevant information to better understand the epidemiology of LNs in Southern Europe and it features some useful points for public health authorities and clinicians. However, additional improvements regarding the registration of these hematological neoplasms can be implemented. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Pla, Solans, Ameijide, Sanvisens, Carulla, Rojas, Alemán, Sáez-Lloret, Díaz-del-Campo, Marcos-Navarro, Sainz-de-Aja, Aizpurua-Atxega, Lopez-de-Munain, Sánchez, Perucha, Franch, Chirlaque, Guevara, Galceran, Merino, Marcos-Gragera and REDECAN working group.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu